openPR Logo
Press release

Defibrillator Market Exclusive Overview Report for 2024-2031

04-12-2024 01:42 AM CET | Associations & Organizations

Press release from: ABNewswire

Defibrillator Market

Defibrillator Market

"Defibrillator Market" in terms of revenue was estimated to be worth $14.92 billion in 2023 and is poised to reach $24.79 billion by 2031
"Defibrillator Market" in terms of revenue was estimated to be worth $14.92 billion in 2023 and is poised to reach $24.79 billion by 2031, growing at a CAGR of 6.8% from 2023 to 2031 according to a new report by InsightAce Analytic.

Get Free Sample Report @ [https://www.insightaceanalytic.com/request-sample/1612]

Latest Drivers Restraint and Opportunities Market Snapshot:

Key factors influencing the global Defibrillator Market are:

* Developments in technology
* Increase in the elderly population
* Growing heart disease prevalence

The following are the primary obstacles to the Defibrillator Market's expansion:

* Cost implication
* Lack of awareness
* Concerns about AIEDs and implantable defibrillators

Future expansion opportunities for the global Defibrillator Market include:

* Defibrillator innovations for the future
* Increasing focus on research and development
* Healthcare facilities are increasingly utilizing ICDs

Market Analysis:

A defibrillator is a medical device that can treat potentially fatal heart arrhythmias. The devices in question work by shocking the heart electrically, which helps to get its rhythm back. The need for improved medical equipment and the rising incidence of cardiovascular disorders are leading to an anticipated expansion of the defibrillator market.

List of Prominent Players in the Defibrillator Market:

* Abbott
* AMI Italia
* Asahi Kasei Corporation
* Avive Solutions Inc.
* AXION Ltd.
* Bexen Cardio
* Biotronik SE & Co. KG
* Boston Scientific Corporation
* BPL Medical Technologies
* Cardiac Science Corporation
* CU Medical Systems
* Element Science Inc.
* HeartHero Inc.
* Jeevtronics Pvt. Ltd.
* LivaNova PLC
* Mediana Co. Ltd.
* Medtronic plc
* Metrax GmbH - PRIMEDIC
* METsis Medikal
* MicroPort Scientific Corporation
* Mindray Medical International Ltd.
* MS Westfalia GmbH
* Nihon Kohden Corporation
* Philips Healthcare
* Progetti SRL - Medical Equipment Solutions
* Schiller AG
* Shenzhen Comen Medical Instruments Ltd.
* Jude Medical, Inc.
* Stryker Corporation

Defibrillator Market Report Scope:

Report Attribute

Specifications

Market size value in 2023

USD 14.92 billion

Revenue forecast in 2031

USD 24.79 billion

Growth rate CAGR

CAGR of 6.8% from 2024 to 2031

Quantitative units

Representation of revenue in US$ Bn, and CAGR from 2024 to 2031

Historic Year

2019 to 2023

Forecast Year

2024-2031

Report coverage

The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends

Segments covered

By Product, End-user

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Recent Developments:

* In December 2023, Asahi Kasei is expanding its chlor-alkali electrolysis cell rental service in a European trial run with Nobian GmbH and LOGISTEED Europe B.V. The Nobian company, headquartered in North Rhine-Westphalia, Germany, is one of the most prominent European chlor-alkali1 producers.
* In November 2023, BIOTRONIK's new manufacturing and research hub for the Asia-Pacific region was recently unveiled. There will be hundreds of people employed in manufacturing, quality assurance, research and development (R&D), sales, and marketing at the 20,000 m site, making it the company's nerve center in The Asia-Pacific region.
* In June 2023, LivaNova PLC announced that Bill Kozy, Interim CEO and Board Chair of LivaNova, will present at the New York Piper Sandler Healthcare Conference.

Curious about this latest version of the report? @ [https://www.insightaceanalytic.com/enquiry-before-buying/1612]

Defibrillator Market Dynamics:

Market Drivers: Growing Heart Disease Prevalence

The defibrillator market will be limited in expansion due to the rising incidence of cardiovascular illnesses. In terms of both death and disability, cardiovascular disease (CVD) ranks first globally. A further contributor to the alarming increase in CVD risk factors is the prevalence of lifestyle-related disorders such as diabetes, hypertension, obesity, dyslipidemia, and dyslipidemia. An increased risk of cardiovascular diseases is significantly and linearly related to hypertension. Defibrillators deliver a powerful shock that supplies the necessary oxygen and blood to the affected organs, leading to market growth.

Challenges: Cost Implication

Defibrillators have high starting prices, which is a big factor that could slow the market's growth. High costs of defibrillators and wearable cardioverter defibrillators may prevent their widespread use, particularly among the economically disadvantaged and in countries with low per capita income, despite the rising number of patients suffering from cardiac illnesses.

North America is Expected to Grow with the Highest CAGR During the Forecast Period

The North America defibrillator Market is likely to register a significant revenue share and develop at a rapid CAGR in the near future. This is due to the increasing investment in R&D and the generally high-quality healthcare services in the area. And since the incidence of cardiac disorders continues to rise, the market in this area is expected to experience excellent growth. The region's high rate of defibrillator adoption is attributable, in part, to its highly developed healthcare infrastructure and sophisticated medical technology. The higher frequency of cardiovascular illnesses in the region has contributed to the market's growth, particularly in the United States.

Segmentation of Defibrillator Market-

By Product-

* Implantable Defibrillators

* Transvenous Implantable Cardioverter Defibrillator (T-ICD)
* Subcutaneous Implantable Cardioverter Defibrillator (S-ICD)
* Cardiac Resynchronization Therapy- Defibrillator (CRT-D)

* External Defibrillators

* Manual External Defibrillator
* Automated External Defibrillators (AEDs)
* Wearable Cardioverter Defibrillators (WCDs)

By End User-

* Hospitals
* Pre-Hospitals
* Public Access Market
* Alternative Care
* Home
* Others

By Region-

North America-

* The US
* Canada
* Mexico

Europe-

* Germany
* The UK
* France
* Italy
* Spain
* Rest of Europe

Asia-Pacific-

* China
* Japan
* India
* South Korea
* Southeast Asia
* Rest of Asia Pacific

Latin America-

* Brazil
* Argentina
* Rest of Latin America

Middle East & Africa-

* GCC Countries
* South Africa
* Rest of Middle East and Africa

For More Customization @ [https://www.insightaceanalytic.com/customisation/1612]

Media Contact
Company Name: InsightAce Analytic Pvt. Ltd
Contact Person: Diana D'Souza
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=defibrillator-market-exclusive-overview-report-for-20242031]
Country: United States
Website: https://www.insightaceanalytic.com/



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Defibrillator Market Exclusive Overview Report for 2024-2031 here

News-ID: 3460865 • Views:

More Releases from ABNewswire

PD-1 and PD-L1 Inhibitors Market is expected to sour at a decent CAGR by 2020-2034, eatimates DelveInsight | Isunakinra, Dato-DXd, ONC-392, ZYNYZ (retifanlimab), Spartalizumab (PDR001), more
PD-1 and PD-L1 Inhibitors Market is expected to sour at a decent CAGR by 2020-20 …
PD-1 and PD-L1 inhibitor companies are Buzzard Pharmaceuticals, AstraZeneca, Daiichi Sankyo, Inc., OncoC4, Inc., BioNTech SE, Incyte, MacroGenics, Novartis, GlaxoSmithKline, Phanes Therapeutics, Compass Therapeutics, HUYABIO International, LLC., Bristol-Myers Squibb, Chugai Pharma USA, Bayer, Istari Oncology, Calico Life Sciences, AbbVie, NeoImmuneTech, Kartos Therapeutics, Inc., CellSight Technologies, Inc., Glenmark Specialty S.A., Jounce Therapeutics, Inc., Turnstone Biologics, and others. (Albany, USA) DelveInsight's PD-1 and PD-L1 Inhibitors Market Insights report includes a comprehensive understanding of
HDAC Inhibitor Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration, companies by DelveInsight | Givinostat, ACS 33, MG 4915, more
HDAC Inhibitor Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, HDAC Inhibitor pipeline constitutes 50+ key companies continuously working towards developing 50+ HDAC Inhibitor treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "HDAC Inhibitor Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the HDAC Inhibitor Market. The HDAC Inhibitor Pipeline report embraces
TROP-2 Inhibitors Market to Grow at a decent CAGR during the Study Period (2020-2034) by DelveInsight | Datopotamab deruxtecan, MK-2870/SKB-264, DB-1305/BNT325, and BIO-106
TROP-2 Inhibitors Market to Grow at a decent CAGR during the Study Period (2020- …
TROP-2 inhibitor companies are Daiichi Sankyo, AstraZeneca, Kelun Biotech, Merck, DualityBio, BioNTech, BiOneCure Therapeutics, and others. (Albany, USA) DelveInsight's TROP-2 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, emerging TROP-2 inhibitors, market share of individual therapies, and current and forecasted TROP-2 inhibitors market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways
EGFR Inhibitors Market to Grow at a decent CAGR during the Study Period (2020-2034) by DelveInsight | Petosemtamab, MCLA-129, Zipalertinib, Furmonertinib, and BLU-945
EGFR Inhibitors Market to Grow at a decent CAGR during the Study Period (2020-20 …
EGFR inhibitor companies are Merus, Cullinan Oncology, Taiho Pharma, Arrivent Biopharma, Blueprint Medicines Corporation, and others. DelveInsight's EGFR Inhibitor Market Insights report includes a comprehensive understanding of current treatment practices, emerging EGFR inhibitors, market share of individual therapies, and current and forecasted EGFR Inhibitor market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan]. Key Takeaways from the

All 5 Releases


More Releases for Defibrillator

Global External Defibrillator Market Insights, Forecast
The global External Defibrillator market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the External Defibrillator market based on company, product type, end user and key regions. This report studies the global market size of External Defibrillator in key regions
Medical Defibrillator(Monophasic)
Asynchronizer:External defibrillator Charging time:At 360J less than 10 sec Paddle configuration:Reusable extermal adult and pediatric paddles Operates from the mains (AC) and with its intemal Lead-acid battery Jiangsu Medwish Network Technology Co., Ltd. is located in Jiangsu, China. It is in a beautiful, clean and convenient environment. We are a professional manufacturer engaged in the research, development, production, sales and export of medical equipment. At the same time, we have a professional foreign
Fully Automatic External Defibrillator Market
https://www.qandqmarketresearch.com/reports/7228183/fully-automatic-external-defibrillator-market-79 The global Fully Automatic External Defibrillator market is valued at xx million US$ in 2017 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 20182025. The objectives of this study are to define, segment, and project the size of the Fully Automatic External Defibrillator market based on company, product type, end user and key regions. This report studies the global market size
2017 EMEA Defibrillator Market Embraces Advancements
Defibrillation is a common treatment for life-threatening cardiac dysrhythmias, ventricular fibrillation and pulseless ventricular tachycardia. Defibrillation consists of delivering a therapeutic dose of electrical energy to the heart with a device called a defibrillator. This depolarizes a critical mass of the heart muscle, terminates the dysrhythmia and allows normal sinus rhythm to be reestablished by the body's natural pacemaker, in the sinoatrial node of the heart. Defibrillators can be external,
Additional Defibrillator Accessories (AED) Market grows with rising adoption of …
Defibrillation is a treatment procedure used during life threatening conditions that affect the rhythm of the heart such as ventricular fibrillation, cardiac arrhythmia, and pulseless ventricular tachycardia. The treatment includes an electric shock given to the heart which results into depolarization of the heart muscles, leading to normal conduction of heart’s electrical impulse. Defibrillator is a device used in this treatment to deliver an electric shock to the heart. It
Global Defibrillators Market, By Product Type (Single Chamber Implantable Cardio …
Defibrillators – Never Skip a Beat Defibrillator is an essential tool in cardiopulmonary resuscitation indicated in cardiac arrhythmia. Various advancements have been observed in defibrillator technology – from manual to automated ones, and implantable defibrillators to ensure constant care for patients suffering from ischemic heart disease or those at high risk of cardiac arrest. A Global Resuscitation Alliance (GRA) was formed in 2016, comprising international health organizations, global resuscitation leaders, and